规格: | 98% |
分子量: | 517.6 |
包装 | 价格(元) |
500ug | 电议 |
1mg | 电议 |
Background:
Telmisartan-d3is intended for use as an internal standard for the quantification of telmisartan by GC- or LC-MS. Telmisartan is a nonpeptide angiotensin (AT) II receptor antagonist which selectively and insurmountably inhibits the AT II receptor subtype AT1(Ki= 3.7 nM).1It also acts as a partial agonist of peroxisome proliferator-activated receptor gamma (PPARγ), activating the receptor to 25-30% of that produced by the full agonist rosiglitazone .2Through these actions, telmisartan potently reduces blood pressure in various animal models of hypertension, diminishing cardiac hypertrophy, cardiovascular and renal risk, and glomerulosclerosis.3,4,5
1.Wienen, W., Hauel, N., Van Meel, J.C.A., et al.Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br. J. Pharmacol.110245-252(1993) 2.Benson, S.C., Pershadsingh, H.A., Ho, C.I., et al.Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension43(5)993-1002(2004) 3.McClellan, K.J., and Markham, A.TelmisartanDrugs56(6)1039-1044(1998) 4.Jugdutt, B.I.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderlyClin. Interv. Aging5403-416(2010) 5.Schmieder, R.E., Bakris, G., and Weir, M.R.Telmisartan in incipient and overt diabetic renal diseaseJ.Nephrol.24(3)263-273(2011)